Non-pharmacological modulation of the autonomic tone to treat heart failure

European Heart Journal

Volumn 35, Issue 2, 2014, Pages 77-85

  Singh, Jagmeet P ^a   Kandala, Jagdesh ^a   John Camm, A ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Autonomic nervous system; Baroreflex sensitivity; Carotid baroreceptor stimulation; Heart rate variability; Parasympathetic nervous system; Renal denervation; Spinal cord stimulation; Sympathetic nervous system; Vagal nerve stimulator

Indexed keywords

AUTONOMIC NERVOUS SYSTEM; CAROTID SINUS PRESSORECEPTOR REFLEX; ELECTRODE; HEART FAILURE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KIDNEY DENERVATION; NERVE STIMULATOR; NEUROMODULATION; PRIORITY JOURNAL; PULSE GENERATOR; REVIEW; SPINAL CORD STIMULATION; SPINAL CORD STIMULATOR; VAGUS NERVE; VAGUS NERVE STIMULATION;

AUTONOMIC NERVOUS SYSTEM; BAROREFLEX SENSITIVITY; CAROTID BARORECEPTOR STIMULATION; HEART RATE VARIABILITY; PARASYMPATHETIC NERVOUS SYSTEM; RENAL DENERVATION; SPINAL CORD STIMULATION; SYMPATHETIC NERVOUS SYSTEM; VAGAL NERVE STIMULATOR;

AUTONOMIC DENERVATION; AUTONOMIC NERVOUS SYSTEM DISEASES; BAROREFLEX; CAROTID SINUS; ELECTRIC STIMULATION THERAPY; HEART FAILURE; HUMANS; KIDNEY; PRESSORECEPTORS; RENIN-ANGIOTENSIN SYSTEM; SPINAL CORD STIMULATION; SYMPATHECTOMY; VAGUS NERVE STIMULATION;

EID: 84892652762     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht436     Document Type: Review

References (104)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013;127:e6-e245.
2. Bristow MR. The adrenergic nervous system in heart failure.NEngl J Med 1984;311: 850-851.
3. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012;33:1058-1066.
4. Floras JS. Arterial baroreceptor and cardiopulmonary reflex control of sympathetic outflow in human heart failure. Ann N Y Acad Sci 2001;940:500-513.
5. Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep 2004;1:45-50.
6. Cohn JN, Levine TB. Angiotensin-converting enzyme inhibition in congestive heart failure: the concept. Am J Cardiol 1982;49:1480-1483.
7. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009;54:1747-1762.
8. Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 2009;54:375-385.
9. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005;111:2837-2849.
10. Ogawa M, Zhou S, Tan AY, Song J, Gholmieh G, Fishbein MC, Luo H, Siegel RJ, Karagueuzian HS, Chen LS, Lin SF, Chen PS. Left stellate ganglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure. J Am Coll Cardiol 2007;50:335-343.
11. Brack KE, Winter J, Ng GA. Mechanisms underlying the autonomic modulation of ventricular fibrillation initiation-tentative prophylactic properties of vagus nerve stimulation on malignant arrhythmias in heart failure. Heart Fail Rev 2012;18: 389-408.
12. LiW, Olshansky B. Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation. Heart Fail Rev 2011;16:137-145.
13. Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 1971;285:877-883.
14. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885.
15. Hwang HS, Hasdemir C, Laver D, Mehra D, Turhan K, Faggioni M, Yin H, Knollmann BC. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 2011;4:128-135.
16. Chou CC, Nguyen BL, Tan AY, Chang PC, Lee HL, Lin FC, Yeh SJ, Fishbein MC, Lin SF, Wu D, Wen MS, Chen PS. Intracellular calcium dynamics and acetylcholine-induced triggered activity in the pulmonary veins of dogs with pacing-induced heart failure. Heart Rhythm 2008;5:1170-1177.
17. Ng J, Villuendas R, Cokic I, Schliamser JE, Gordon D, Koduri H, Benefield B, Simon J, Murthy SN, Lomasney JW,Wasserstrom JA, Goldberger JJ, Aistrup GL, Arora R. Autonomic remodeling in the left atrium and pulmonary veins in heart failure: creation of a dynamic substrate for atrial fibrillation. Circ Arrhythm Electrophysiol 2011;4: 388-396.
18. Liang C, Rounds NK, Dong E, Stevens SY, Shite J, Qin F. Alterations by norepinephrine of cardiac sympathetic nerve terminal functionand myocardial beta-adrenergic receptor sensitivity in the ferret: normalization by antioxidant vitamins. Circulation 2000;102:96-103.
19. Eisenhofer G, Rundquist B, Aneman A, Friberg P, Dakak N, Kopin IJ, Jacobs MC, Lenders JW. Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab 1995;80:3009-3017.
20. Lambert E, Straznicky N, Schlaich M, Esler M, Dawood T, Hotchkin E, Lambert G. Differing pattern of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension 2007;50:862-868.
21. Hogarth AJ, Graham LN, Mary DA, Greenwood JP. Gender differences in sympathetic neural activation following uncomplicated acute myocardial infarction. Eur Heart J 2009;30:1764-1770.
22. Floras JS, Mak S. Muscle sympathetic nerve activity in women and men following acute myocardial infarction: a meaningful difference? Eur Heart J 2009;30: 1692-1694.
23. Malliani A, Pagani M, Lombardi F, Furlan R, Guzzetti S, Cerutti S. Spectral analysis to assess increased sympathetic tone in arterial hypertension. Hypertension 1991;17(4 Suppl):III36-III42.
24. Furlan R, Guzzetti S, Crivellaro W, Dassi S, Tinelli M, Baselli G, Cerutti S, Lombardi F, Pagani M, Malliani A. Continuous 24-hour assessment of the neural regulation of systemic arterial pressure andRRvariabilities in ambulant subjects. Circulation 1990;81:537-547.
25. Adamopoulos S, Piepoli M, McCance A, Bernardi L, Rocadaelli A, Ormerod O, Forfar C, Sleight P, Coats AJ. Comparison of different methods for assessing sympathovagal balance in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1992;70:1576-1582.
26. Malliani A, Pagani M, Furlan R, Guzzetti S, Lucini D, Montano N, Cerutti S, Mela GS. Individual recognition by heart rate variability of two different autonomic profiles related to posture. Circulation 1997;96:4143-4145.
27. Piotrowicz E, Baranowski R, Piotrowska M, Zielinski T, Piotrowicz R. Variable effects of physical training of heart rate variability, heart rate recovery, and heart rate turbulence in chronic heart failure. Pacing Clin Electrophysiol 2009;32(Suppl 1):S113-S115.
28. La Rovere MT, Pinna GD, Maestri R, Barlera S, Bernardinangeli M, Veniani M, Nicolosi GL, Marchioli R, Tavazzi L. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial. Eur J Heart Fail 2012;14:1410-1419.
29. Bauer A, Kantelhardt JW, Barthel P, Schneider R, Makikallio T, Ulm K, Hnatkova K, Schomig A, Huikuri H, Bunde A, MalikM, Schmidt G. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet 2006;367:1674-1681.
30. La RovereMT, Pinna GD, Hohnloser SH, Marcus FI, Mortara A, Nohara R, Bigger JT Jr,CammAJ, Schwartz PJ. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 2001;103:2072-2077.
31. Sleight P, La Rovere MT, Mortara A, Pinna G, Maestri R, Leuzzi S, Bianchini B, Tavazzi L, Bernardi L. Physiology and pathophysiology of heart rate and blood pressure variability in humans: is power spectral analysis largely an index of baroreflex gain? Clin Sci (Lond) 1995;88:103-109.
32. Perrone-Filardi P, Paolillo S, Dellegrottaglie S, Gargiulo P, Savarese G, Marciano C, Casaretti L, Cecere M, Musella F, Pirozzi E, Parente A, Cuocolo A. Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal. Heart 2011;97:1828-1833.
33. Bengel FM, Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol 2004;11:603-616.
34. Merchant FM, DecGW, Singh JP. Implantable sensors for heart failure. Circ Arrhythm Electrophysiol 2010;3:657-667.
35. Lin YH, Lin C, Lo MT, Lin HJ, Wu YW, Hsu RB, Chao CL, Hsu HC, Wang PC, WuVC,Wang SS, Lee CM, Chien KL, Ho YL, Chen MF, Peng CK. The relationship between aminoterminal propeptide of type III procollagen and heart rate variability parameters in heart failure patients: a potential serum marker to evaluate cardiac autonomic control and sudden cardiac death. Clin Chem Lab Med 2010;48: 1821-1827.
36. Whellan DJ, Ousdigian KT, Al-Khatib SM, Pu W, Sarkar S, Porter CB, Pavri BB, O'Connor CM. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Programto Access and ReviewTrending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. J Am Coll Cardiol 2010;55: 1803-1810.
37. Singh JP, Rosenthal LS, Hranitzky PM, Berg KC, Mullin CM, Thackeray L, Kaplan A. Device diagnostics and long-term clinical outcome in patients receiving cardiac resynchronization therapy. Europace 2009;11:1647-1653.
38. Fantoni C, Raffa S, Regoli F, Giraldi F, La Rovere MT, Prentice J, Pastori F, Fratini S, Salerno-Uriarte JA, Klein HU, Auricchio A. Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure. J Am Coll Cardiol 2005;46:1875-1882.
39. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376: 1903-1909.
40. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, AbrahamWT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-1281.
41. Hering D, Lambert EA, Marusic P,Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013;61: 457-464.
42. Ljungqvist A,Wagermark J. The adrenergic innervation of intrarenal glomerular and extra-glomerular circulatory routes. Nephron 1970;7:218-229.
43. Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Bohm M, Krum H. Sympatho-renal axis in chronic disease. Clin Res Cardiol 2011;100:1049-1057.
44. Mahfoud F, Luscher TF, Andersson B, Baumgartner I, Cifkova R, Dimario C, Doevendans P, Fagard R, Fajadet J, Komajda M, Lefevre T, Lotan C, Sievert H, Volpe M, Widimsky P, Wijns W, Williams B, Windecker S, Witkowski A, Zeller T, Bohm M. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013;34: 2149-2157.
45. Investigators. SH. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011;57:911-917.
46. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009;361:932-934.
47. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka PA, Krum H, Schlaich M, Esler M, Bohm M. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013;128:132-140.
48. Davies JE, Manisty CH, Petraco R, Barron AJ, Unsworth B, Mayet J, Hamady M, Hughes AD, Sever PS, Sobotka PA, Francis DP. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 2013;162:189-192.
49. Ozaki Y. European Society of Cardiology (ESC) Congress Report from Munich 2012. Circ J 2012;76:2530-2535.
50. Hospital BP. Phase 3 study of renal denervation that improves symptoms of heart failure and enhances life quality in advanced heart failure. Available at http://www. clinicaltrials.gov/ct2/show/NCT01538992?Term=NCT01538992&rank=1 (25 October 2013).
51. Vascular M. Renal denervation in patients with chronic heart failure and renal impairment. Available at http://www.clinicaltrials.gov/ct2/show/ NCT01392196? Term=SymplicityHF+%28NCT01392196%29&rank=1(25October2013).
52. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M, Hoppe UC. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012;59: 901-909.
53. Zile MR, Little WC. Effects of autonomic modulation: more than just blood pressure. J Am Coll Cardiol 2012;59:910-912.
54. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Bohm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011;123:1940-1946.
55. Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger HR, Wirth K, Bohm M. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension 2012;60:172-178.
56. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, Shirokova N, Karaskov A, Mittal S, Steinberg JS. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012;60:1163-1170.
57. Ukena C, Bauer A, Mahfoud F, Schreieck J, Neuberger HR, Eick C, Sobotka PA, Gawaz M, Bohm M. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol 2012;101:63-67.
58. Ukena C, Mahfoud F, Spies A, Kindermann I, Linz D, Cremers B, Laufs U, Neuberger HR, Bohm M. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int J Cardiol 2012;167:2846-2851.
59. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003;5:659-667.
60. Vanoli E, De Ferrari GM, Stramba-Badiale M, Hull SS Jr, Foreman RD, Schwartz PJ. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res 1991;68:1471-1481.
61. Billman GE, Schwartz PJ, Stone HL. Baroreceptor reflex control of heart rate: a predictor of sudden cardiac death. Circulation 1982;66:874-880.
62. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998;351:478-484.
63. Heck C, Helmers SL,DeGiorgioCM.Vagus nerve stimulation therapy, epilepsy, and device parameters: scientific basis and recommendations for use. Neurology 2002; 59(6 Suppl. 4):S31-S37.
64. Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005;58:347-354.
65. Schwartz PJ, De Ferrari GM, Sanzo A, Landolina M, Rordorf R, Raineri C, Campana C, Revera M, Ajmone-Marsan N, Tavazzi L, Odero A. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail 2008;10:884-891.
66. Milby AH, Halpern CH, Baltuch GH. Vagus nerve stimulation for epilepsy and depression. Neurotherapeutics 2008;5:75-85.
67. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004;109:120-124.
68. De Ferrari GM, Schwartz PJ. Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions. Heart Fail Rev 2011;16: 195-203.
69. Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 2008;118:863-871.
70. Ando M, Katare RG, Kakinuma Y, Zhang D, Yamasaki F, Muramoto K, Sato T. Efferent vagal nerve stimulation protects heart against ischemia-induced arrhythmias by preserving connexin43 protein. Circulation 2005;112:164-170.
71. Zhang Y, Popovic ZB, Bibevski S, Fakhry I, Sica DA, VanWagoner DR, Mazgalev TN. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacingmodel. Circ Heart Fail 2009;2:692-699.
72. Van Stee EW. Autonomic innervation of the heart. Environ Health Perspect 1978;26: 151-158.
73. Armour JA. Cardiac neuronal hierarchy in health and disease. Am J Physiol Regul Integr Comp Physiol 2004;287:R262-R271.
74. Schauerte P, Mischke K, Plisiene J,Waldmann M, Zarse M, Stellbrink C, Schimpf T, Knackstedt C, Sinha A, Hanrath P. Catheter stimulation of cardiac parasympathetic nerves in humans: a novel approach to the cardiac autonomic nervous system. Circulation 2001;104:2430-2435.
75. Anholt TA, Ayal S, Goldberg JA. Recruitment and blocking properties of the CardioFit stimulation lead. J Neural Eng 2011;8:034004.
76. De Ferrari GM, Crijns HJ, Borggrefe M, Milasinovic G, Smid J, Zabel M, Gavazzi A, Sanzo A, Dennert R, Kuschyk J, Raspopovic S, Klein H, Swedberg K, Schwartz PJ. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J 2011;32:847-855.
77. Hauptman PJ, Schwartz PJ, Gold MR, Borggrefe M, Van Veldhuisen DJ, Starling RC, Mann DL. Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J 2012;163:954-962 e1.
78. Corporation BS. Neural cardiac therapy for heart failure study. Available at http://clinicaltrials.gov/ct2/show/NCT01385176?Term=Nectar-HF&rank=1. (25October 2013).
79. Sabbah HN, Ilsar I, Zaretsky A, Rastogi S,Wang M, Gupta RC. Vagus nerve stimulation in experimental heart failure. Heart Fail Rev 2011;16:171-178.
80. Bianchi S, Rossi P, Della Scala A, Kornet L, Pulvirenti R, Monari G, Di Renzi P, Schauerte P, Azzolini P. Atrioventricular (AV) node vagal stimulation by transvenous permanent lead implantation to modulate AV node function: safety and feasibility in humans. Heart Rhythm 2009;6:1282-1286.
81. McCubbin JW, Green JH, Page IH. Baroceptor function in chronic renal hypertension. Circ Res 1956;4:205-210.
82. ChapleauMW, Hajduczok G, Abboud FM. Mechanisms of resetting of arterial baroreceptors: an overview. Am J Med Sci 1988;295:327-334.
83. Thrasher TN. Unloading arterial baroreceptors causes neurogenic hypertension. Am J Physiol Regul Integr Comp Physiol 2002;282:R1044-R1053.
84. Biaggioni I, Whetsell WO, Jobe J, Nadeau JH. Baroreflex failure in a patient with central nervous system lesions involving the nucleus tractus solitarii. Hypertension 1994;23:491-495.
85. Robertson D, Hollister AS, Biaggioni I, Netterville JL, Mosqueda-Garcia R, Robertson RM. The diagnosis and treatment of baroreflex failure. N Engl J Med 1993;329:1449-1455.
86. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, HallerH, Pichlmaier AM, Luft FC, Jordan J. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010;55:619-626.
87. Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, Luft FC, Haller H, Menne J, Engeli S, Ceral J, Eckert S, Erglis A, Narkiewicz K, Philipp T, de Leeuw PW. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010;56: 1254-1258.
88. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de LeeuwPW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebocontrolled rheos pivotal trial. J Am Coll Cardiol 2011;58:765-773.
89. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-termfollow-up in the Rheos Pivotal Trial. J AmSoc Hypertens 2012;6: 152-158.
90. Creager MA. Baroreceptor reflex function in congestive heart failure. Am J Cardiol 1992;69:10G-15G; discussion 15G-16G.
91. Zucker IH, Hackley JF, Cornish KG, Hiser BA, Anderson NR, Kieval R, Irwin ED, Serdar DJ, Peuler JD, Rossing MA. Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension 2007;50:904-910.
92. Higashi T, Kobayashi N, Hara K, Shirataki H, Matsuoka H. Effects of angiotensin II type 1 receptor antagonist on nitric oxide synthase expression and myocardial remodeling in Goldblatt hypertensive rats. J Cardiovasc Pharmacol 2000;35:564-571.
93. Nishida Y, Ding J, Zhou MS, Chen QH, Murakami H, Wu XZ, Kosaka H. Role of nitric oxide in vascular hyper-responsiveness to norepinephrine in hypertensive Dahl rats. J Hypertens 1998;16:1611-1618.
94. CVRx I. Health Outcomes Prospective Evaluation for Heart Failure With EF ? 40%. In CVRx I. Rheos HOPE4HF Study. Available at http://clinicaltrials.gov/ show/NCT00718939 (25 October 2013).
95. Georgakopoulos D, Little WC, Abraham WT,Weaver FA, Zile MR. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail 2011;17:167-178.
96. CVRx I. BarostimHOPE4HF Study.Available at http://www.clinicaltrials.gov/ ct2/show/NCT01720160?Term=NCT01720160&rank=1 (25October 2013).
97. Management MCRD. Acute Carotid Sinus Endovascular Stimulation II Study.Available at http://www.clinicaltrials.gov/ct2/show/NCT01458483?Term= NCT01458483&rank=1 (25 October 2013).
98. Olgin JE, Takahashi T, Wilson E, Vereckei A, Steinberg H, Zipes DP. Effects of thoracic spinal cord stimulation on cardiac autonomic regulation of the sinus and atrioventricular nodes. J Cardiovasc Electrophysiol 2002;13:475-481.
99. Lopshire JC, Zhou X, Dusa C, Ueyama T, Rosenberger J, Courtney N, Ujhelyi M, Mullen T, Das M, Zipes DP. Spinal cord stimulation improves ventricular function and reduces ventricular arrhythmias in a canine postinfarction heart failure model. Circulation 2009;120:286-294.
100. IssaZF,ZhouX, Ujhelyi MR,Rosenberger J, Bhakta D,GrohWJ, Miller JM, ZipesDP. Thoracic spinal cord stimulation reduces the risk of ischemic ventricular arrhythmias in a postinfarction heart failure canine model. Circulation 2005;111: 3217-3220.
101. Medical SJ. Spinal cord stimulation for heart failure as a restorative treatment. Available at http://www.clinicaltrials.gov/ct2/show/NCT01362725?Term= NCT01362725&rank=1 (25October 2013).
102. Management MCRD. Determining the feasibility of spinal cord neuromodulation for the treatment of chronic heart failure. Available at http://www. clinicaltrials.gov/ct2/show/NCT01112579?Term=NCT01112579&rank=1 (25 October 2013).
103. Medical SJ. Trial of Autonomic neuroModulation for trEatment of Chronic Heart Failure. Available at http://www.clinicaltrials.gov/ct2/show/NCT01820130? Term=NCT01820130&rank=1 (25 October 2013).
104. Kobayashi M, Sakurai S, Takaseya T, Shiose A, Kim HI, Fujiki M, Karimov JH, Dessoffy R, Massiello A, Borowski AG, Van Wagoner DR, Jung E, Fukamachi K. Effects of percutaneous stimulation of both sympathetic and parasympathetic cardiac autonomic nerves on cardiac function in dogs. Innovations (Phila) 2012;7:282-289.